Available Technologies - Search Results
| Title: | Novel Retinoblastoma Binding Protein-Related Gene And Potential Use As Cancer Vaccine |
|---|---|
| UC Case No: | 2001-352-2-ott |
| Categories: |
Pharmaceuticals:
Cancer,
Immune and Inflammatory Disorders,
Vaccines
Biotechnology: Antibodies, Diagnostics, DNA/RNA Tools, Drug Targets and Screening Tools, Gene and Cell Therapy, Gene Expression, Protein Folding and Interactions, Research Tools |
| Background: | The central objective in the development of an effective immunotherapy is the identification of tumor antigens that can elicit antibody and cellular immune responses in humans. Human autologous or allogeneic antibodies from cancer patients are an alternative to the use of monoclonal antibodies. Though not as specific as monoclonal antibodies, serum antibodies are useful probes to identify tumor-associated antigen epitopes relevant to immune responses in cancer patients. |
| Technology: | Researchers at the University of California, Irvine, used human IgG antibodies to identify a novel retinoblastoma binding protein-related gene (RBP1L1) that encodes a nonameric antigen epitope. The epitope was recognized by IgG antibodies that were isolated from breast cancer patients. RBP-CT mRNA is expressed at high levels in various human carcinomas and in normal testis and expression is limited or absent in other normal tissues. |
| Application: | The properties of RBP-CT as a molecular marker may be used for the development of novel diagnostic tools for the detection of human malignancies. The identified antigenic peptide epitope may also serve as a potential target for a tumor vaccine. |
| Contact: |
Maria Tkachuk, Licensing Associate Office of Technology Alliances University of California, Irvine 380 University Tower Irvine, CA 92697-7700 Phone: (949) 824-2288 FAX: (949) 824-2899 Email: mtkachuk@uci.edu |
| Patent Status: | U.S. Patent No. 7,259,236 |
| UCI School: | College of Medicine |
| Department: | Microbiology & Molecular Genetics |
